C9: A Potential Drug Target for Cell-Cell Adhesion and Actinin Regulation

Target Name: C9

NCBI ID: G735

C9: A Potential Drug Target for Cell-Cell Adhesion and Actinin Regulation

C9, also known as ARMD15, is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of actinin, a protein that is involved in cell-cell adhesion. C9 is a potential drug target and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of C9 as a potential drug target was made by a team of researchers at the University of California, San Diego. The researchers used a variety of techniques, including yeast two-hybrid assays, GFP-fused cell lines, and biochemical assays, to identify C9 as a protein that was involved in the regulation of actinin. The researchers also used techniques such as mass spectrometry and affinity purification to confirm that C9 was indeed involved in this process.

C9 is a protein that is expressed in the ER and is involved in the regulation of actinin, a protein that is involved in cell-cell adhesion.

Actinin is a protein that is involved in many different processes in the cell, including cell-cell adhesion, cytoskeletal organization, and intracellular signaling. It is also involved in the regulation of various cellular processes, including cell growth, apoptosis, and autophagy.

C9 is shown to play a role in the regulation of actinin by interacting with the protein, alpha-actinin. This interaction allows C9 to regulate the level of actinin in the cell, which in turn can affect the behavior of the cell.

The researchers are currently working to identify the underlying mechanisms that regulate C9 and its interaction with alpha-actinin. They are also exploring the potential clinical applications of C9 as a drug target.

In addition to its role in cell-cell adhesion and actinin regulation, C9 is also involved in the regulation of many other cellular processes. It is involved in the regulation of cell growth, apoptosis, and autophagy, and is also involved in the regulation of various signaling pathways, including the TGF-beta pathway.

C9 is a protein that is expressed in the ER and is involved in the regulation of actinin, a protein that is involved in cell-cell adhesion.

C9 is also a protein that is involved in the regulation of many other cellular processes. It is involved in the regulation of cell growth, apoptosis, and autophagy, and is also involved in the regulation of various signaling pathways, including the TGF-beta pathway.

The discovery of C9 as a potential drug target has the potential to lead to new treatments for a variety of diseases. By targeting the regulation of actinin, C9 may be able to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, C9 is a protein that is expressed in the ER and is involved in the regulation of actinin, a protein that is involved in cell-cell adhesion. The discovery of C9 as a potential drug target has the potential to lead to new treatments for a variety of diseases. Further research is needed to understand the underlying mechanisms that regulate C9 and its interaction with alpha-actinin, and to explore the potential clinical applications of C9 as a drug target.

Protein Name: Complement C9

Functions: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells (PubMed:9634479, PubMed:9212048, PubMed:26841934). C9 is the pore-forming subunit of the MAC (PubMed:4055801, PubMed:26841934, PubMed:30111885)

More Common Targets